Conestoga Capital Advisors Has Boosted Stake in West Pharmaceutical Svsc (WST); Vale S A (VALE) Valuation Declined While Silchester International Investors Llp Lowered Its Stake

June 21, 2018 - By reb123z

Vale S.A. (NYSE:VALE) Logo

Silchester International Investors Llp decreased its stake in Vale S A (VALE) by 39.71% based on its latest 2018Q1 regulatory filing with the SEC. Silchester International Investors Llp sold 14.49 million shares as the company’s stock declined 3.15% with the market. The institutional investor held 22.01 million shares of the precious metals company at the end of 2018Q1, valued at $279.94M, down from 36.50 million at the end of the previous reported quarter. Silchester International Investors Llp who had been investing in Vale S A for a number of months, seems to be less bullish one the $63.27 billion market cap company. The stock decreased 3.16% or $0.41 during the last trading session, reaching $12.58. About 22.45 million shares traded or 1.80% up from the average. Vale S.A. (NYSE:VALE) has risen 69.29% since June 21, 2017 and is uptrending. It has outperformed by 56.72% the S&P500. Some Historical VALE News: 10/04/2018 – Moody’s Affirms Vale S.A. Ratings With Stable Outlook; 20/05/2018 – Vale Awaits Battery Revolution to Make Nickel Output Economic; 26/04/2018 – VALE EXEC SAYS COMPANY WILL NOT FLOOD THE MARKET WITH ORE FROM CARAJAS; 20/04/2018 – Vale says court postponed deadline for Samarco compensation plan; 25/04/2018 – VALE 1Q NET OPER REV. $8.60B, EST. $8.72B; 15/05/2018 – REG-CLOSING OF YARA ACQUISITION OF VALE CUBATāO FERTILIZANTES COMPLEX IN BRAZIL; 11/04/2018 – Brazil antitrust regulator to reassess Yara-Vale fertilizer deal; 21/03/2018 – EXCLUSIVE- MITSUI, BRADESPAR EXPECT TO MAINTAIN THEIR VALE STAKES, NOT DIVESTING IN MEDIUM TERM; 20/03/2018 – S&PGR Revises Vale Outlk To Stable From Pos; Ratings Affirmed; 21/03/2018 – Vale announces final tender results of cash tender offer for 5.875% guaranteed notes due 2021

Conestoga Capital Advisors Llc increased its stake in West Pharmaceutical Svsc Inc (WST) by 25.27% based on its latest 2018Q1 regulatory filing with the SEC. Conestoga Capital Advisors Llc bought 5,305 shares as the company’s stock rose 6.13% while stock markets declined. The institutional investor held 26,298 shares of the basic industries company at the end of 2018Q1, valued at $2.32 million, up from 20,993 at the end of the previous reported quarter. Conestoga Capital Advisors Llc who had been investing in West Pharmaceutical Svsc Inc for a number of months, seems to be bullish on the $7.43B market cap company. The stock decreased 0.94% or $0.96 during the last trading session, reaching $100.92. About 276,030 shares traded. West Pharmaceutical Services, Inc. (NYSE:WST) has declined 5.12% since June 21, 2017 and is downtrending. It has underperformed by 17.69% the S&P500. Some Historical WST News: 07/03/2018 HEALTHPRIZE & WEST EXTEND CONNECTED HEALTH PARTNERSHIP; 19/03/2018 – West to Showcase DAIKYO PLASCAP® RUV One-Step Press-Fit Vial Closure Solution at PDA Annual Meeting; 26/04/2018 – WEST PHARMACEUTICAL SERVICES INC – ESTIMATES ITS 2018 CAPITAL SPENDING WILL BE LESS THAN $150 MLN; 03/05/2018 – West Pharma Presenting at Bank of America Conference May 15; 26/04/2018 – WEST PHARMACEUTICAL SERVICES INC WST.N SEES FY 2018 SALES $1.72 BLN TO $1.73 BLN; 20/04/2018 – DJ West Pharmaceutical Services Inc, Inst Holders, 1Q 2018 (WST); 30/05/2018 – West Pharma Closes Above 200-Day Moving Average: Technicals; 03/05/2018 – WEST PHARMACEUTICAL BOOSTS 4Q DIV/SHR TO 15C FROM 14C, EST. 15C; 15/03/2018 – GAMIDA CELL APPOINTS SHAI LANKRY AS CHIEF FINANCIAL OFFICER; 26/04/2018 – West Pharma Sees FY Adj EPS $2.80-Adj EPS $2.90

Since May 9, 2018, it had 1 insider purchase, and 3 selling transactions for $9.11 million activity. Another trade for 5,000 shares valued at $486,200 was sold by Malone Daniel. The insider ZENNER PATRICK J bought 275 shares worth $24,444.

Investors sentiment decreased to 1.08 in Q1 2018. Its down 0.09, from 1.17 in 2017Q4. It turned negative, as 31 investors sold WST shares while 88 reduced holdings. 33 funds opened positions while 95 raised stakes. 67.31 million shares or 0.22% more from 67.16 million shares in 2017Q4 were reported. Westpac Bk reported 0% of its portfolio in West Pharmaceutical Services, Inc. (NYSE:WST). Stone Ridge Asset Mgmt Llc stated it has 0.05% in West Pharmaceutical Services, Inc. (NYSE:WST). Stephens Ar reported 2,541 shares. Tcw Group invested 0.49% of its portfolio in West Pharmaceutical Services, Inc. (NYSE:WST). Minnesota-based Riverbridge Prtnrs Ltd Llc has invested 0.79% in West Pharmaceutical Services, Inc. (NYSE:WST). Archford Capital Strategies Limited Liability Com invested in 50 shares or 0% of the stock. Connecticut-based Aqr Cap Limited has invested 0% in West Pharmaceutical Services, Inc. (NYSE:WST). Eaton Vance Mngmt has invested 0.06% of its portfolio in West Pharmaceutical Services, Inc. (NYSE:WST). Dubuque State Bank And Tru Co has 0% invested in West Pharmaceutical Services, Inc. (NYSE:WST) for 266 shares. Plante Moran Financial Advsr Ltd Limited Liability Company reported 6 shares. Kings Point Cap owns 0.16% invested in West Pharmaceutical Services, Inc. (NYSE:WST) for 8,920 shares. Neuberger Berman Group holds 3.17M shares. Citigroup reported 10,331 shares. Barclays Public Limited Com holds 0% of its portfolio in West Pharmaceutical Services, Inc. (NYSE:WST) for 30,516 shares. State Treasurer State Of Michigan reported 27,000 shares or 0.02% of all its holdings.

Conestoga Capital Advisors Llc, which manages about $1.75B and $2.61B US Long portfolio, decreased its stake in Aci Worldwide Inc (NASDAQ:ACIW) by 76,420 shares to 2.08 million shares, valued at $49.28M in 2018Q1, according to the filing. It also reduced its holding in Mesa Labs Inc (NASDAQ:MLAB) by 14,927 shares in the quarter, leaving it with 408,877 shares, and cut its stake in Healthstream Inc (NASDAQ:HSTM).

Among 6 analysts covering West Pharmaceutical Services (NYSE:WST), 3 have Buy rating, 1 Sell and 2 Hold. Therefore 50% are positive. West Pharmaceutical Services had 16 analyst reports since August 4, 2015 according to SRatingsIntel. The rating was downgraded by Bank of America to “Sell” on Wednesday, April 25. On Friday, September 15 the stock rating was upgraded by Jefferies to “Buy”. The company was downgraded on Tuesday, August 4 by Zacks. The firm earned “Hold” rating on Monday, September 11 by Jefferies. Jefferies maintained West Pharmaceutical Services, Inc. (NYSE:WST) rating on Thursday, February 15. Jefferies has “Buy” rating and $115.0 target. On Tuesday, October 17 the stock rating was downgraded by Bank of America to “Hold”. The firm earned “Market Perform” rating on Wednesday, September 21 by Wells Fargo. Wells Fargo upgraded West Pharmaceutical Services, Inc. (NYSE:WST) on Friday, October 28 to “Outperform” rating. Janney Capital initiated the shares of WST in report on Friday, January 8 with “Buy” rating. Wells Fargo maintained West Pharmaceutical Services, Inc. (NYSE:WST) on Friday, October 27 with “Outperform” rating.

More news for West Pharmaceutical Services, Inc. (NYSE:WST) were recently published by: Streetinsider.com, which released: “West Pharma (WST) Names Bernard Birkett as CFO” on June 21, 2018. Prnewswire.com‘s article titled: “West Appoints Bernard Birkett to Chief Financial Officer” and published on June 21, 2018 is yet another important article.

More recent Vale S.A. (NYSE:VALE) news were published by: Forbes.com which released: “How Is Vale Likely To Grow In The Next 2 Years?” on June 14, 2018. Also Seekingalpha.com published the news titled: “Cobalt 27 Has A Rapidly Growing Portfolio Of 11 (Now 12) Cobalt And Nickel Streaming And Royalty Deals” on June 21, 2018. Seekingalpha.com‘s news article titled: “Wheaton Precious Metals buys cobalt stream from Vale mine in $390M deal” with publication date: June 11, 2018 was also an interesting one.

Analysts await Vale S.A. (NYSE:VALE) to report earnings on July, 26. They expect $0.21 earnings per share, up 16.67% or $0.03 from last year’s $0.18 per share. VALE’s profit will be $1.06B for 14.98 P/E if the $0.21 EPS becomes a reality. After $0.37 actual earnings per share reported by Vale S.A. for the previous quarter, Wall Street now forecasts -43.24% negative EPS growth.

Among 27 analysts covering Vale S.A. (NYSE:VALE), 14 have Buy rating, 1 Sell and 12 Hold. Therefore 52% are positive. Vale S.A. had 79 analyst reports since August 3, 2015 according to SRatingsIntel. The stock of Vale S.A. (NYSE:VALE) has “Market Perform” rating given on Thursday, March 1 by Cowen & Co. The firm has “Neutral” rating by Goldman Sachs given on Thursday, June 9. The stock of Vale S.A. (NYSE:VALE) earned “Outperform” rating by Credit Suisse on Tuesday, December 5. The company was upgraded on Monday, October 19 by UBS. Credit Suisse maintained Vale S.A. (NYSE:VALE) rating on Friday, May 26. Credit Suisse has “Hold” rating and $800 target. As per Wednesday, January 20, the company rating was downgraded by HSBC. The firm has “Hold” rating given on Monday, August 28 by Jefferies. The stock has “Overweight” rating by Barclays Capital on Monday, January 9. Credit Suisse maintained Vale S.A. (NYSE:VALE) rating on Tuesday, June 27. Credit Suisse has “Hold” rating and $800 target. Jefferies maintained the shares of VALE in report on Thursday, February 15 with “Hold” rating.

West Pharmaceutical Services, Inc. (NYSE:WST) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts